HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2005.09.077v1 47/8/1507    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Cesario, D. A. Articles by Dec, G. W. Search for Related Content PubMed PubMed Citation Articles by Cesario, D. A. Articles by Dec, G. W.

STATE-OF-THE-ART PAPER

Implantable Cardioverter- Defibrillator Therapy in Clinical Practice

David A. Cesario, MD, PhD^_* and G. William Dec, MD^,_*

^_* University of California-Irvine, Irvine, California
Cardiology Division, Massachusetts General Hospital, Heart Failure and Transplantation Unit, Boston, Massachusetts.

Manuscript received August 26, 2005; accepted September 29, 2005.

^_* Reprint requests and correspondence: Dr. G. William Dec, Cardiology Division, Massachusetts General Hospital, Heart Failure and Transplantation Unit, Bigelow 800, Mailstop 817, 55 Fruit Street, Boston, Massachusetts 02114. (Email: gdec{at}partners.org).

Pharmacologic treatment of heart failure has led to dramatic improvements in survival and quality of life. Nonetheless, heart failure often progresses despite treatment with diuretics, angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, aldosterone antagonists, and digoxin. Further, despite a steady decline in the risk of death from pump failure, many patients remain at high risk for sudden cardiac death. The annual incidence of sudden cardiac death in the U.S. alone has been estimated at 184,000 to over 400,000 cases. During the past decade, substantial advances have been made in the use of device-based therapy for this population. The role of the implantable cardioverter-defibrillator (ICD) continues to evolve in routine heart failure management. The current status of ICD therapy in the treatment of heart failure patients based on randomized clinical trial results and published practice guidelines is summarized in this review.

Abbreviations and Acronyms   ARVD = arrhythmogenic right ventricular dysplasia   ECG = electrocardiogram   EP = electrophysiological   HCM = hypertrophic cardiomyopathy   ICD = implantable cardioverter-defibrillator   LQTS = long QT syndrome   NYHA = New York Heart Association   SCD = sudden cardiac death

This article has been cited by other articles:

				A. Tosaki and I. Edes The role of peroxiredoxins in ischemia-reperfusion-induced cardiac damage Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2586 - H2587. [Full Text] [PDF]